RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints
Status:
Completed
Trial end date:
2021-04-28
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind placebo controlled one-site proof-of-concept study in
subjects with erosive osteoarthritis (OA) of interphalangeal (IP) finger joints.
A total of 100 subjects will be enrolled into the study: 48 weeks placebo controlled
double-blind phase with denosumab 60mg every 12 weeks, followed by a 48-week open-label phase
in which all subjects will receive denosumab.